Robotic-assisted transperineal fusion biopsy led to relatively low rates of prostate cancer upgrading and downgrading in a single-center study.

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...

Prostate cancer stands as a prevalent threat to men's health, ranking second in cancer-related deaths in the United States. Each year, approximately 250,000 men in the U.S. receive a prostate cancer ...

Individual patient data (IPD) analysis of early PSA nadir in ARASENS, LATITUDE, and TITAN: Training and validation of a novel model. Assessing genomic instability (GI) by shallow whole-genome ...

Extended analyses: Combined androgen blockade (CAB) therapy with bicalutamide vs. luteinizing hormone-releasing hormone agonist (LHRHa) monotherapy in Japanese men with untreated advanced prostate ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug ...

Benefits include better discrimination between risk levels. (HealthDay News) — Patient-centered pathology reports (PCPR) help patients to understand prostate cancer results better than current ...

Prostate cancer has distinct genetic properties in different groups of men that could be targeted to improve patient outcomes, new research suggests. Prostate cancer has distinct genetic properties in ...